Focus: Shattuck Labs is a public biotechnology company headquartered in Austin, TX, developing an immunotherapy platform focused on oncology. The company is in early-stage clinical development with a pipeline concentrated in Phase 1 programs.
Profile data last refreshed 12h ago · AI intelligence enriched 3w ago
Shattuck Labs offers platform potential and near-term pipeline catalysts but faces material cash constraints and limited hiring, making it suitable only for risk-tolerant candidates aligned with clinical-stage execution.
Help build intelligence for Shattuck Labs
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Shattuck Labs's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Analysts Offer Insights on Healthcare Companies: Sysmex (OtherSSMXF), Icon (ICLR) and Shattuck Labs (STTK) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Sysmex (OtherSSMXF), Icon (ICLR) and Shattuck Labs (STTK) The Globe and Mail
Shattuck Labs Announces Two Poster Presentations at UEG Week 2026 - Investing News Network
Shattuck Labs Announces Two Poster Presentations at UEG Week 2026 Investing News Network
UBS initiates Shattuck Labs stock with buy rating on drug advantage By Investing.com - Investing.com South Africa
UBS initiates Shattuck Labs stock with buy rating on drug advantage By Investing.com Investing.com South Africa
UBS initiates Shattuck Labs stock with buy rating on drug advantage - Investing.com
UBS initiates Shattuck Labs stock with buy rating on drug advantage Investing.com
UBS initiates Shattuck Labs stock with buy rating on drug advantage - Investing.com UK
UBS initiates Shattuck Labs stock with buy rating on drug advantage Investing.com UK
Biohaven Licenses IgG Degrader Portfolio to Ono for $80 Million Upfront - finance.biggo.com
Biohaven Licenses IgG Degrader Portfolio to Ono for $80 Million Upfront finance.biggo.com
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia.
Author's response to the editorial commentary, "TL1A and DR3 in IBD: from mucosal immunopathology to a new era of targeted therapy".
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo